ABLi Therapeutics has appointed Dr. Rachelle S. Doody, a veteran in neurodegeneration drug development, to its Board of Directors. Dr. Doody brings over a decade of experience from Roche and Axxium Life, focusing on diseases like Alzheimer's and Parkinson's. Her expertise will guide ABLi as it prepares Phase 3 trials for Parkinson’s, Multiple System Atrophy, and Dementia with Lewy Body. This move strengthens ABLi's efforts to develop therapies that target the underlying causes of these neurodegenerative diseases, including their lead drug candidate risvodetinib, which shows promise in slowing Parkinson’s progression.
Valneva declared its shares and voting rights status as of May 31, 2026, reporting 189,771,237 ordinary shares and a total of 204,238,965 exercisable voting rights after accounting for double voting rights on some shares. This update is important for...
Valneva announced an update on its share capital and voting rights as of May 31, 2026. The company reported a total of 189,771,237 ordinary shares with a nominal value of €0.15 each, and a total of 204,363,287 voting rights including suspended rights...
Integrated Quantum Technologies introduced VEIL™, a privacy-focused tool integrated into Snowflake's AI Data Cloud, which removes personally identifiable information (PII) from data before it is used in AI and machine learning models. This approach a...
Bluejay Diagnostics announced a private placement to raise up to $23.6 million, including $8.5 million upfront, to extend its cash runway into early 2027. The funds will support FDA submission and commercialization of its rapid sepsis testing system,...
Ed Yardeni, president of Yardeni Research, forecasts the Federal Reserve will raise interest rates at its July 29 meeting, a view that contrasts with the market's low expectations for a rate hike this summer. Yardeni cites a resilient economy, strong...
